The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Liposome-Anchored Vascular Endothelial Growth Factor Aptamers
Abstract
Nuclease-resistant aptamers identified from randomized nucleic acid libraries represent a novel class of drug candidates. Aptamers are synthesized chemically and therefore can be readily modified with functional groups that modulate their properties. We report here on the preparation, initial characterization, and functional properties of a nuclease-resistant vascular endothelial growth factor (VEGF) aptamer anchored in liposome bilayers through a lipid group on the aptamer. While the high-affinity binding to VEGF is maintained, the plasma residence time of the liposome-anchored aptamer is considerably improved compared with that of the free aptamer. The lipid group attachment and/or liposome anchoring leads to a dramatic improvement in inhibitory activity of the aptamer toward VEGF-induced endothelial cell proliferation in vitro and vascular permeability increase and angiogenesis in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiogenesis in cancer, vascular, rheumatoid and other disease
Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0195-27 · Cited by 7,627
Cited by
Aptamers as targeted therapeutics: current potential and challenges
Zhou, J., & Rossi, J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.199 · Cited by 2,221
In Vitro Selection of Functional Nucleic Acids
Wilson, D. S., & Szostak, J. W. (1999) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.68.1.611 · Cited by 1,206
Aptamers: An Emerging Class of Therapeutics
Nimjee, S. M., Rusconi, C. P., & Sullenger, B. A. (2005) · Annual Review of Medicine · doi:10.1146/annurev.med.56.062904.144915 · Cited by 937
Nanoparticle-Aptamer Bioconjugates
Farokhzad, O. C., Jon, S., Khademhosseini, A., Tran, T.-N. T., LaVan, D. A., & Langer, R. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2550 · Cited by 897
Functional Aptamers and Aptazymes in Biotechnology, Diagnostics, and Therapy
Famulok, M., Hartig, J. S., & Mayer, G. (2007) · Chemical Reviews · doi:10.1021/cr0306743 · Cited by 887
Aptamers come of age – at last
Bunka, D. H. J., & Stockley, P. G. (2006) · Nature Reviews Microbiology · doi:10.1038/nrmicro1458 · Cited by 695
Zylberberg, C., & Matosevic, S. (2016) · Drug Delivery · doi:10.1080/10717544.2016.1177136 · Cited by 627
Nimjee, S. M., White, R. R., Becker, R. C., & Sullenger, B. A. (2017) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-104558 · Cited by 607
Kraft, J. C., Freeling, J. P., Wang, Z., & Ho, R. J. Y. (2014) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23773 · Cited by 606
Recent Progress in Aptamer Discoveries and Modifications for Therapeutic Applications
Ni, S., Zhuo, Z., Pan, Y., Yu, Y., Li, F., Liu, J., Wang, L., Wu, X., Li, D., Wan, Y., et al. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c05750 · Cited by 589
Aptamers as therapeutic and diagnostic agents
Brody, E. N., & Gold, L. (2000) · Reviews in Molecular Biotechnology · doi:10.1016/s1389-0352(99)00004-5 · Cited by 494
Discovery and development of anticancer aptamers
Ireson, C. R., & Kelland, L. R. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0172 · Cited by 481
Röthlisberger, P., & Hollenstein, M. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.04.007 · Cited by 413
Ferreira, C. S. M., Matthews, C. S., & Missailidis, S. (2006) · Tumor Biology · doi:10.1159/000096085 · Cited by 407
Reversible Cell‐Specific Drug Delivery with Aptamer‐Functionalized Liposomes
Cao, Z., Tong, R., Mishra, A., Xu, W., Wong, G. C. L., Cheng, J., & Lu, Y. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200901452 · Cited by 372
Antidote-mediated control of an anticoagulant aptamer in vivo
Rusconi, C. P., Roberts, J. D., Pitoc, G. A., Nimjee, S. M., White, R. R., Quick, G., Scardino, E., Fay, W. P., & Sullenger, B. A. (2004) · Nature Biotechnology · doi:10.1038/nbt1023 · Cited by 339
Chemical Modifications of Nucleic Acid Aptamers for Therapeutic Purposes
Ni, S., Yao, H., Wang, L., Lu, J., Jiang, F., Lu, A., & Zhang, G. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081683 · Cited by 321
Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice
McNamara, J. O., Kolonias, D., Pastor, F., Mittler, R. S., Chen, L., Giangrande, P. H., Sullenger, B., & Gilboa, E. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33365 · Cited by 310
Aptamers: A Review of Their Chemical Properties and Modifications for Therapeutic Application
Adachi, T., & Nakamura, Y. (2019) · Molecules · doi:10.3390/molecules24234229 · Cited by 300
Developing aptamers into therapeutics
White, R. R., Sullenger, B. A., & Rusconi, C. P. (2000) · Journal of Clinical Investigation · doi:10.1172/jci11325 · Cited by 295
Nanopreparations for organelle-specific delivery in cancer
Biswas, S., & Torchilin, V. P. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.11.004 · Cited by 292
Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development
Drummond, D. C., Noble, C. O., Hayes, M. E., Park, J. W., & Kirpotin, D. B. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21358 · Cited by 289
Generation of Species Cross-reactive Aptamers Using “Toggle” SELEX
White, R., Rusconi, C., Scardino, E., Wolberg, A., Lawson, J., Hoffman, M., & Sullenger, B. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0495 · Cited by 284
Nanotechnology and aptamers: applications in drug delivery
Levy-Nissenbaum, E., Radovic-Moreno, A. F., Wang, A. Z., Langer, R., & Farokhzad, O. C. (2008) · Trends in Biotechnology · doi:10.1016/j.tibtech.2008.04.006 · Cited by 270
Nucleic acid aptamers in cancer research, diagnosis and therapy
Ma, H., Liu, J., Ali, M. M., Mahmood, M. A. I., Labanieh, L., Lu, M., Iqbal, S. M., Zhang, Q., Zhao, W., & Wan, Y. (2015) · Chemical Society Reviews · doi:10.1039/c4cs00357h · Cited by 265
Molecular imaging with nanoparticles: giant roles for dwarf actors
Debbage, P., & Jaschke, W. (2008) · Histochemistry and Cell Biology · doi:10.1007/s00418-008-0511-y · Cited by 264
Aptamer-guided nanomedicines for anticancer drug delivery
Alshaer, W., Hillaireau, H., & Fattal, E. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.09.011 · Cited by 187
Selection of Nucleic Acid Aptamers Targeting Tumor Cell-Surface Protein Biomarkers
Mercier, M.-C., Dontenwill, M., & Choulier, L. (2017) · Cancers · doi:10.3390/cancers9060069 · Cited by 113
Metadata
- Authors
- Willis, M. C., Collins, B., Zhang, T., Green, L. S., Sebesta, D. P., Bell, C., Kellogg, E., Gill, S. C., Magallanez, A., Knauer, S., Bendele, R. A., Gill, P. S., & Janjić, N.
- Venue
- Bioconjugate Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 1998-07-10
- Volume
- 9
- Issue
- 5
- Pages
- 573-582
- ISSN
- 1043-1802 (ISSN-L)
- 1520-4812
- OpenAlex
- W2059259822
- Cited by
- 181
- References
- 1
- FWCI
- 1.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.